Design of a phase II dose range finding, efficacy and safety study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in relapsing multiple sclerosis patients

被引：0
|
作者：
Montalban, X. [1 ]
Bojanowski, J. [2 ]
Martin, E. [2 ]
Willmer, J. [2 ]
机构：
[1] Vall dHebron Univ Hosp & Res Inst, Barcelona, Spain
[2] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P675
引用
收藏
页码：324 / 324
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of AIN457 (secukinumab) in patients with relapsing multiple sclerosis: design of an adaptive dose-ranging phase 2 study
    Rudick, R.
    Wiendl, H.
    Steinman, L.
    Bar-Or, A.
    Bhore, R.
    Bennett, D.
    Bieniek, M.
    de Vera, A.
    Montalban, X.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 518 - 518
  • [42] Design of a Phase 2b Dose-finding Trial to Evaluate Safety and Efficacy of the CNS-penetrant BTK Inhibitor SAR442168 in Patients with Relapsing Forms of Multiple Sclerosis
    Traboulsee, Anthony
    LaGanke, Christopher
    Montalban, Xavier
    Wray, Sibyl
    Zhang, Xinyan
    Matta, Andre
    Turner, Timothy
    Wallstrom, Erik
    NEUROLOGY, 2020, 94 (15)
  • [43] First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes
    Jurczak, Wojciech
    Rule, Simon
    Townsend, William
    Tucker, David
    Dyroff, Martin
    Sarholz, Barbara
    Scheele, Jurgen
    Gribben, John G.
    Zinzani, Pier Luigi
    BLOOD, 2017, 130
  • [44] Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study
    Genovese, Mark C.
    Spindler, Alberto
    Sagawa, Akira
    Park, Won
    Dudek, Anna
    Kivitz, Alan
    Chao, Jeannie
    Chan, Lai Shan Melanie
    Witcher, Jennifer
    Barchuk, William
    Nirula, Ajay
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 969 - 976
  • [45] Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial
    An, Gang
    Zhou, Daobin
    Zhao, Weili
    Zhou, Keshu
    Li, Jianyong
    Zhou, Jianfeng
    Xie, Liping
    Jin, Jie
    Zhong, Liye
    Yan, Lingzhi
    Guo, Haiyi
    Du, Chenmu
    Huang, Jane
    Novotny, William
    Zhong, Jinhua
    Qiu, Lugui
    BLOOD, 2020, 136
  • [46] Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
    Overman, Michael
    Javle, Milind
    Davis, Richard E.
    Vats, Pankaj
    Kumar-Sinha, Chandan
    Xiao, Lianchun
    Mettu, Niharika B.
    Parra, Edwin R.
    Benson, Al B.
    Lopez, Charles D.
    Munugalavadla, Veerendra
    Patel, Priti
    Tao, Lin
    Neelapu, Sattva
    Maitra, Anirban
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [47] Phase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies
    Jurczak, W.
    Rule, S.
    Townsend, W.
    Tucker, D.
    Sarholz, B.
    Scheele, J.
    Gribben, J.
    Zinzani, P. L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] Preliminary safety and efficacy of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL).
    Jones, Jeffrey Alan
    Andritsos, Leslie A.
    Lucas, David M.
    Lozanski, Gerard
    Hutchinson, Terri
    Sexton, Jennifer L.
    Harris, Pamela Jo
    Grever, Michael R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Phase I/II, first in human trial of the Bruton's tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies.
    Rule, Simon
    Tucker, David
    Kalapur, Anup
    Sarholz, Barbara
    Scheele, Jurgen
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
    Cohen, Jeffrey A.
    Comi, Giancarlo
    Arnold, Douglas L.
    Bar-Or, Amit
    Selmaj, Krzysztof W.
    Steinman, Lawrence
    Havrdova, Eva K.
    Cree, Bruce A. C.
    Montalban, Xavier
    Hartung, Hans-Peter
    Huang, Vivian
    Frohna, Paul
    Skolnick, Brett E.
    Kappos, Ludwig
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (09) : 1255 - 1262
12345